Oral parity is so important for myeloma patients—imagine your doctor recommends by-mouth treatment, but since there's no federal oral parity law, insurance doesn't cover it the same as IV infusion. Keep the IMF fighting for health equity:https://t.co/pQ15im0Yyt #kNOwMyeloma
Great news for patients. Happy to see Carvitki approval jumping to 2L for the treatment of adult patients with RRMM who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. #MMSM
The second BCMAxCD3 targeted bispecific antibody, Elrexfio (elranatamab) is now approved by @US_FDA for RRMM patients who have received at least 4 prior lines of therapy. #mmsm@pfizer https://t.co/ToSHPFIPeL
Attention #myeloma patients! The Patient Advocate Foundation Medical Insurance Premium Assistance Co-Pay Relief Fund is open. Don't miss out on support for co-pays, co-insurance, deductibles, and medical insurance premiums. https://t.co/7ZnjNNu8SQ
#mmsm
DYK #multiplemyeloma disproportionately impacts African Americans? To get ahead of this disease, we're working with patient advocates to increase the number of African American participants in clinical trials.
“Multiple myeloma is 2X more prevalent in the African American community, most of the time when African Americans are diagnosed, they’ve never heard of the disease. That’s not okay, we’ve got to do something about that.” — Valarie Traynham. https://t.co/VOcZxzv6SP
#IMFMPOWER
We need better immunotherapy treatments for extramedullary #myeloma in R/R pts. Results from this Phase II trial of daratumumab with DCEP with... - https://t.co/wHiEpZmEtN #ScholarAlerts
When you shop at https://t.co/97Zo6f9r00 and designate the International Myeloma Foundation as your preferred charity, Amazon donates 0.5% of all purchases you make to the IMF, at no added cost to you. https://t.co/pdCnn76rZi
❤️ this video of Support Group Leaders telling what they wished others knew about #myeloma.
Filmed at the annual support group leaders summit.
#BloodCancerAwarenessMonth
https://t.co/VYGPzEvt2n
Did you know that while myeloma is most frequently found in people aged 65-74, it is also being diagnosed in individuals who are much younger? @Karyopharm is supporting our goal of #myeloma education and awareness this #BloodCancerAwarenessMonth! Thank you!
#kNOwMyeloma
How should patients frame questions to their doctor? Either at relapse or at least once or twice a year, patients need to initiate "What next?" questions with their doctor. I also think physicians need to initiate this conversation occasionally. #cancer#myeloma#mmsm